Inhibitor Therapeutics (OTCMKTS:INTI) Issues Quarterly Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) posted its quarterly earnings data on Friday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Performance

Shares of INTI stock opened at $0.08 on Friday. The company’s fifty day moving average price is $0.09 and its 200-day moving average price is $0.07. The stock has a market cap of $14.35 million, a PE ratio of -8.30 and a beta of -0.58. Inhibitor Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.12.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.